Sun Siyuan, Zhang Guangheng, Lv Shimeng, Sun Jinhui
First Clinical Medical College, Beijing University of Chinese Medicine, Beijing, China.
First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China.
Front Microbiol. 2024 Aug 21;15:1407991. doi: 10.3389/fmicb.2024.1407991. eCollection 2024.
Cirrhosis, a pathological stage that develops from various chronic liver diseases, is characterized by liver fibrosis, pseudolobular formation, and chronic inflammation. When it progresses to the decompensated phase, the mortality rate of cirrhosis can reach 80%. The role of gut microbiota in the progression of liver diseases has received significant attention. Numerous studies have shown that regulating gut microbiota has significant therapeutic effects on preventing and reversing liver cirrhosis. This article reviewed the mechanisms by which gut microbiota influence liver cirrhosis, explaining the effective therapeutic effects of traditional Chinese medicine. Through multi-directional regulation involving signaling pathways, gut microbiota diversity, and restoration of intestinal barrier function, traditional Chinese medicine has been promising in ameliorating liver cirrhosis, providing treatment options and pharmacological guidance for the occurrence and development of liver cirrhosis.
肝硬化是由各种慢性肝病发展而来的一个病理阶段，其特征为肝纤维化、假小叶形成和慢性炎症。当进展到失代偿期时，肝硬化的死亡率可达80%。肠道微生物群在肝脏疾病进展中的作用已受到广泛关注。大量研究表明，调节肠道微生物群对预防和逆转肝硬化具有显著的治疗效果。本文综述了肠道微生物群影响肝硬化的机制，阐述了中药的有效治疗作用。通过涉及信号通路、肠道微生物群多样性和肠道屏障功能恢复的多向调节，中药在改善肝硬化方面具有广阔前景，为肝硬化的发生发展提供了治疗选择和药理学指导。
